Carlyle Bets Big On Late-Stage Biotech With Abingworth Buy
Partners Set Up Launch Tx
Tapping into Abingworth’s pioneering clinical co-development model, the private equity behemoth is using that experience to form Launch Therapeutics which will seek to partner with biotech and biopharma on "best‐in‐class, late‐stage clinical assets [and] bring life‐saving therapies to market better, faster and cheaper."
You may also be interested in...
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Nandini Piramal, executive director, Piramal Enterprises, discusses how things have shaped in the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing "framework" deployed by industry.
The ABV 8 fund will invest $15m to $30m per company across the range from start-ups to development-stage companies.